Cimon Medical develops and manufactures novel Doppler ultrasound technology for healthcare and aim to become the market leader in continuous direct monitoring of blood-flow.
The first product to be released in Q4 22 is NeoDoppler – non-invasive continuous monitoring of blood-flow in the brain of premature or critically ill infants.
The disruptive Cimon ultrasound technology is highly scalable with many potential clinical applications.
Cimon Medical develops and manufactures novel Doppler ultrasound technology for healthcare and aim to become the market leader in continuous direct monitoring of blood-flow.
The first product under development is NeoDoppler – non-invasive continuous monitoring of blood-flow in the brain of premature or critically ill infants
The disruptive Cimon ultrasound technology is highly scalable with many potential clinical applications.
Technology
Technology
Cimon Medical is the owner of a unique proprietary technology for continuous monitoring of blood-flow using non-invasive Doppler ultrasound. The core of the innovation is a coin-sized ultrasound probe constructed as a single element transducer with an unfocused beam that can measure blood circulation continuously by illuminating a 1×4 cm cylindric area of the tissue and capture all blood flow signals in this volume simultaneously.
This type of monitoring has not been possible before
Technology
Technology
Cimon Medical is the owner of a unique proprietary technology for continuous monitoring of blood-flow using non-invasive Doppler ultrasound. The core of the innovation is a coin-sized ultrasound probe constructed as a single element transducer with an unfocused beam that can measure blood circulation continuously by illuminating a 1×4 cm cylindric area of the tissue and capture all blood flow signals in this volume simultaneously.
This type of monitoring has not been possible before
NeoDoppler
Our first product
15% of infants require intensive care in their first month of life, and fluctuations in brain blood-flow is increasing the risk of brain damage for these babies. Currently, no direct continuous measurement of brain blood-flow is available in spite of a clear clinical unmet need.
NeoDoppler is providing direct, non-invasive, continuous monitoring of blood-flow in the brain of premature or critically ill babies. NeoDoppler is suitable for all infants in the Newborn Intensive Care Unit (NICU), and in infants undergoing cardiac interventions.
NeoDoppler
15% of infants require intensive care in their first month of life, and fluctuations in brain blood-flow is increasing the risk of brain damage for these babies. Currently, no direct continuous measurement of brain blood-flow is available in spite of a clear clinical unmet need.
NeoDoppler is providing direct, non-invasive, continuous monitoring of blood-flow in the brain of premature or critically ill babies. NeoDoppler is suitable for all infants in the Newborn Intensive Care Unit (NICU), and in infants undergoing cardiac interventions.
About us
Cimon Medical AS is based on groundbreaking, patented technology originating from the internationally renowned ultrasound environment at The Norwegian University of Science and Technology (NTNU) and St. Olavs University Hospital (St. Olavs), both located in Trondheim, Norway.
The company’s vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood-flow.
Email: contact@cimonmedical.com
Phone: +47 900 82 124
ULTRASOUND
CIRCULATION MONITORING
CIRCULATION MONITORING
ULTRASOUND
CIRCULATION MONITORING
CIRCULATION MONITORING
Continuous blood flow monitoring for early detection and diagnosis.
Cimon Medical is based on groundbreaking, patented technology originating from the internationally renowned ultrasound environment at NTNU and St. Olavs Hospital.
Our vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood flow within: newborn intensive care, peripheral arterial disease and sepsis diagnosis.
Continuous blood flow monitoring for early detection and diagnosis.
Cimon Medical is based on groundbreaking, patented technology originating from the internationally renowned ultrasound environment at NTNU and St. Olavs Hospital.
Our vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood flow within: newborn intensive care, peripheral arterial disease and sepsis diagnosis.
History
CIMON Medical is founded based on technology from the Department of Circulation and Medical Imaging (ISB) at the Norwegian University of Science and Technology (NTNU). This particular technology is invented by Professor Hans Torp, a driving force in the Trondheim ultrasound community.
In Trondheim and at ISB, innovation in ultrasound goes back a long time. Already in the early 70’s the department developed the first instrument that could non-invasively measure blood flow in the aorta, replacing catheter-based measurements of pressure drops in heart valve stenosis.
The innovation was picked up by Vingmed, and by 1986 spun out into Vingmed Sound. Since then, Trondheim and NTNU has been at the forefront of ultrasound innovation, developing Doppler ultras
Presently, CIMON Medical is industrializing ultrasound innovations from Trondheim, allowing for the first time continuous monitoring of blood flow for a variety of applications.
Timeline
- 1976 – 2015
Doppler Ultrasound for clinical use is developed at the internationally renowned Department of Circulation and Imaging at the Norwegian Technical University NTNU) in Trondheim, Norway
- 2015 – 2017
Idea and concept for Cimon technology developed by Prof. Hans Torp
- 2017 – 2019
Pilot- and clinical studies with prototypes initiated at St.Olavs and Oslo Univ. Hospital
- 2020
Industrialization process with selected manufacturing partners
- Q4 2021
Launch of 1st regulatory approved product – NeoDoppler
- Q4 2022
Launch of 2nd regulatory approved product – Fetal monitoring
Continuous blood flow monitoring for early detection and diagnosis.
Continuous blood flow monitoring for early detection and diagnosis.
Cimon Medical is based on groundbreaking, patented technol- ogy originating from the internationally renowned ultrasound environment at NTNU and St. Olavs Hospital.
Our vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood flow within: newborn intensive care, peripheral arterial disease and sepsis diagnosis.
Cimon NeoDoppler
Cimon NeoDoppler
CIMON Medical is founded based on technology from the Department of Circulation and Medical Imaging (ISB) at the Norwegian University of Science and Technology (NTNU). This particular technology is invented by Professor Hans Torp, a driving force in the Trondheim ultrasound community.
In Trondheim and at ISB, innovation in ultrasound goes back a long time. Already in the early 70’s the department developed the first instrument that could non-invasively measure blood flow in the aorta, replacing catheter-based measurements of pressure drops in heart valve stenosis.
The innovation was picked up by Vingmed, and by 1986 spun out into Vingmed Sound. Since then, Trondheim and NTNU has been at the forefront of ultrasound innovation, developing Doppler ultras
Presently, CIMON Medical is industrializing ultrasound innovations from Trondheim, allowing for the first time continuous monitoring of blood flow for a variety of applications.
User independent and robust positioning
Small and easily attachable
Continuous monitoring of an area
System cos < 3.000€
Disposable probe model
Cimon NeoDoppler
Cimon NeoDoppler
CIMON Medical is founded based on technology from the Department of Circulation and Medical Imaging (ISB) at the Norwegian University of Science and Technology (NTNU). This particular technology is invented by Professor Hans Torp, a driving force in the Trondheim ultrasound community.
In Trondheim and at ISB, innovation in ultrasound goes back a long time. Already in the early 70’s the department developed the first instrument that could non-invasively measure blood flow in the aorta, replacing catheter-based measurements of pressure drops in heart valve stenosis.
The innovation was picked up by Vingmed, and by 1986 spun out into Vingmed Sound. Since then, Trondheim and NTNU has been at the forefront of ultrasound innovation, developing Doppler ultras
Presently, CIMON Medical is industrializing ultrasound innovations from Trondheim, allowing for the first time continuous monitoring of blood flow for a variety of applications.
Applications in Different Dimensions
Applications in Different Dimensions
Generic System Architecture
Generic System Architecture
Most components are generic. Only minor in- vestments needed for software adaption and transducer layout to support develop of new products.
Multiple market segments
Multiple market segments
Cimon technology has been demonstrated for a number of clinical applications within neonatal care, intensive medicine and vascular surgery.
Flexible system adaption
Flexible system adaption
Cimon technology can be stand-alone or integrated in third-party monitoring solutions (OEM).
Adaptable to multiple settings
Adaptable to multiple settings
Cimon Technology can be used both before and after intervention in the hospital ward, during surgical interventions, to support ambulant emergency services or for personalized home-based monitoring.
Technology applications
Neonatal monitoring
The need
1 in 10 children are born prematurely each year. Preterm children have large fluctuations in cerebral blood flow, increasing the risk of brain damage substantially. Premature birth increases the risk of brain damage. Currently there exists no direct continuous measurement of cerebral blood flow.
The solution
Using a new non-invasive ultrasound probe and application specific signal analysis, our technology measures and detects changes in cerebral blood flow in real-time. This allows clinicians to act early to prevent brain damage by timing medical interventions. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 23 neonates born at different gestational ages was completed during spring 2018. The study indicated that the CIMON Medical technology provides reliable and continuous cerebral blood flow data of high quality. As of autumn 2018, four further studies is being initiated at St. Olav’s Hospital, Oslo University Hospital (Rikshospitalet), and The Hospital for Sick Children in Canada.
Sepsis diagnosis
The need
Sepsis is a bacterial infection with high mortality. Globally, 120 million people develop severe infections each year. In 30 million of these cases, the infection progresses to sepsis. 30 % of these patients eventually die of the infection. Accurately sepsis diagnosis at an early stage is critical as the risk of death increases with every passing hour the condition goes untreated. Despite this, there are currently no diagnostic tools for early detection of sepsis.
The solution
Changes in micro circulation is an early indicator of sepsis development. Using a new, non-invasive, ultrasound probe and application specific signal analysis, our technology enables early detection of sepsis through continuous monitoring of microcirculation. This enables early medical intervention with antibiotics. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 4 patients was completed during spring 2018. The study verified the CIMON Medical technology against established methods. Two further are initiated at St. Olav’s Hospital.
Diabetes monitoring
The need
Peripheral arterial disease (PAD) is a disease leading to tissue damage, foot ulcers, and amputation. The disease is caused by occlusion of the arteries and is commonly treated with surgery to remove occlusions. In 2010, 202 million people around the world were living with PAD. Currently, there is no simple, user-independent tool for detection of initial occlusion in the arteries, nor tools for detecting complications after surgery.
The solution
Using a new non-invasive ultrasound probe and application specific signal analysis, our technology enables both early diagnosis of PAD as well as complication detection after surgery. The technology can also be used as a tool for decision support during surgical treatment of PAD. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 10 patients was completed during the spring of 2017. The study verified the CIMON Medical technology against established methods. Three further studies are initiated at St. Olav’s Hospital, Oslo University Hospital, and Hospital of Southern Norway.
Technology applications
Neonatal monitoring
The need
1 in 10 children are born prematurely each year. Preterm children have large fluctuations in cerebral blood flow, increasing the risk of brain damage substantially. Premature birth increases the risk of brain damage. Currently there exists no direct continuous measurement of cerebral blood flow.
The solution
Using a new non-invasive ultrasound probe and application specific signal analysis, our technology measures and detects changes in cerebral blood flow in real-time. This allows clinicians to act early to prevent brain damage by timing medical interventions. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 23 neonates born at different gestational ages was completed during spring 2018. The study indicated that the CIMON Medical technology provides reliable and continuous cerebral blood flow data of high quality. As of autumn 2018, four further studies is being initiated at St. Olav’s Hospital, Oslo University Hospital (Rikshospitalet), and The Hospital for Sick Children in Canada.
Sepsis diagnosis
The need
Sepsis is a bacterial infection with high mortality. Globally, 120 million people develop severe infections each year. In 30 million of these cases, the infection progresses to sepsis. 30 % of these patients eventually die of the infection. Accurately sepsis diagnosis at an early stage is critical as the risk of death increases with every passing hour the condition goes untreated. Despite this, there are currently no diagnostic tools for early detection of sepsis.
The solution
Changes in micro circulation is an early indicator of sepsis development. Using a new, non-invasive, ultrasound probe and application specific signal analysis, our technology enables early detection of sepsis through continuous monitoring of microcirculation. This enables early medical intervention with antibiotics. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 4 patients was completed during spring 2018. The study verified the CIMON Medical technology against established methods. Two further are initiated at St. Olav’s Hospital.
Diabetes monitoring
The need
Peripheral arterial disease (PAD) is a disease leading to tissue damage, foot ulcers, and amputation. The disease is caused by occlusion of the arteries and is commonly treated with surgery to remove occlusions. In 2010, 202 million people around the world were living with PAD. Currently, there is no simple, user-independent tool for detection of initial occlusion in the arteries, nor tools for detecting complications after surgery.
The solution
Using a new non-invasive ultrasound probe and application specific signal analysis, our technology enables both early diagnosis of PAD as well as complication detection after surgery. The technology can also be used as a tool for decision support during surgical treatment of PAD. The technology is operator independent and does not require ultrasound expertise.
Clinical activity
A feasibility study with 10 patients was completed during the spring of 2017. The study verified the CIMON Medical technology against established methods. Three further studies are initiated at St. Olav’s Hospital, Oslo University Hospital, and Hospital of Southern Norway.
Team
Dr. Tormod Thomsen CEO
Dr. Tormod Thomsen CEO
20 years of experience from medical technology and healthcare related industry as founder; CEO and other management positions. Extensive experience in product development, international business development, sales and marketing.
20 years of experience from medical technology and healthcare related industry as founder; CEO and other management positions. Extensive experience in product development, international business development, sales and marketing.
Prof. Hans Torp Inventor
Prof. Hans Torp Inventor
Professor in medical technology at the Department of Circulation and Medical Imaging, NTNU. More than 40 years of experience in research and development of ul- trasound Doppler technology and have received several awards for his work.
Professor in medical technology at the Department of Circulation and Medical Imaging, NTNU. More than 40 years of experience in research and development of ul- trasound Doppler technology and have received several awards for his work.
Our partners
St.Olavs Hospital collaborates closely with NTNU on education and has a special responsibility for sharing knowledge and supporting professional development in the specialist health services in central Norway.
The regional hospital is responsible for the most specialized treatment services, and therefore has patients throughout central Norway. St. Olavs Hospital also has some national functions and collaborates with other university hospitals.
St.Olavs Hospital collaborates closely with NTNU on education and has a special responsibility for sharing knowledge and supporting professional development in the specialist health services in central Norway.
The regional hospital is responsible for the most specialized treatment services, and therefore has patients throughout central Norway. St. Olavs Hospital also has some national functions and collaborates with other university hospitals.
NTNU is Norway’s university for higher ed- ucation in technology and natural sciences.
NTNU has 9 faculties and 55 institutes and more than 100 laboratories. The university employs approximately 5360 academic staff and has 40 000 students.
The university is recognized for a broad cooperation with national and international businesses and has an annual budget of approx. 9 billion Norwegian kroner.
NTNU is Norway’s university for higher ed- ucation in technology and natural sciences.
NTNU has 9 faculties and 55 institutes and more than 100 laboratories. The university employs approximately 5360 academic staff and has 40 000 students.
The university is recognized for a broad cooperation with national and international businesses and has an annual budget of approx. 9 billion Norwegian kroner.
NTNU Technology Transfer AS works to create value from research based ideas that come out of The Norwegian University of Science and Technology (NTNU) and The Central Norway Regional Health Authority (Helse Midt-Norge).
NTNU Technology Transfers goal is to create benefit to society from these ideas in the form of new products, new services, new industries and new jobs.
NTNU Technology Transfer AS works to create value from research based ideas that come out of The Norwegian University of Science and Technology (NTNU) and The Central Norway Regional Health Authority (Helse Midt-Norge).
NTNU Technology Transfers goal is to create benefit to society from these ideas in the form of new products, new services, new industries and new jobs.
Email: contact@cimonmedical.com
Phone: +47 911 65 775
Email: contact@cimonmedical.com
Phone: +47 911 65 775
Email: contact@cimonmedical.com
Phone: +47 911 65 775